Please assess the completion status of the following clinical trial:

Trial Title: Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients more than 18 years-old.~2. Patients diagnosed with NVAF registered in primary care according to ICD-10.~3. Patients initiating apixaban (naïve or VKA experienced), VKA (naïve or VKA experienced), dabigatran or rivaroxaban for the SPAF indication.~4. Continuous enrolment in the 12 months pre-index.~Exclusion Criteria:~1. Patients with valvular heart disease (ICD 10: I05.0-I05.09, I08.0-I08.9) including patients with mitral prosthetic valves.~2. Lost to follow-up (e.g. transfer to primary care center non-ICS).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1. Apixaban (Type: None): Patients who are on treatment with apixaban.~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~1b. patients who previously have been treated with VKA in the 12 months before index date.
- Group 2. VKA (Type: None): Patients who are on treatment with VKA.~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~2b. patients who previously have been treated with VKA in the 12 months before index date.
- Group 3. Dabigatran (Type: None): Patients who are on treatment with dabigatran.~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~3b. patients who previously have been treated with VKA in the 12 months before index date.
- Group 4. Rivaroxaban (Type: None): Patients who are on treatment with rivaroxaban.~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~4b. patients who previously have been treated with VKA in the 12 months before index date.

Based on this trial design, predict the completion outcome and termination type (if applicable).